NOTE: This story originally ran in the June 13th issue of Bio-IT World, viewable here. By Kevin Davies, Bio-IT World June 13, 2012 | ALISO VIEJO, CA – What makes Ambry Genetics different? It might be the relaxed surfing culture at the genetic diagnostics firm’s southern California headquarters, the humorous candor of founder and CEO Charles Dunlop,…

IRVINE, CA, May 8 – Ernst & Young LLP today announced the 15 finalists for the Ernst & Young Entrepreneur Of The Year® 2012 Awards in Orange County. The awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. These…

ALISO VIEJO, Calif., SOUTH SAN FRANCISCO, Calif. – April 12, 2012 – Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today the launch of Fluidigm (NASDAQ:FLDM) BioMark™ HD and Access Array™ System-based genomic research services. These services provide gene expression, SNP genotyping, and sample preparation for targeted sequencing using next-generation sequencers,…

ALISO VIEJO, Calif. – March 27, 2012 – Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces the First-Tier Exome™ test.  The First-Tier Exome reports on all Human Gene Mutation Database (HGMD)-defined genes. The role of genes in human disease has only been defined in approximately 20% (~4,400…

ALISO VIEJO, Calif., and BALTIMORE, Md. – February 29, 2012 – Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces specific results from one of three recent diagnoses using its proprietary new Clinical Diagnostic Exome™.  Four individuals with rare genetic conditions for which the cause could not previously…

Marks First in Industry Additional Information To Be Reported in Coming Weeks   ALISO VIEJO, Calif. – January 19, 2012 – Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces the successful completion of the first three diagnostic cases using its proprietary Clinical Diagnostic Exome™.  Three individuals…

Aliso Viejo, CA – December 21, 2011 – Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today that they have officially launched their Illumina MiSeq Next-Gen sequencing services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider processing…

SEATTLE, WA — November 29, 2011 – EMC Corporation (NYSE: EMC) today announced that Ambry Genetics®, a leading commercial provider of clinical diagnostic and genomic services, has deployed EMC® Isilon® scale-out NAS to power its advanced gene sequencing operations, enabling Ambry to advance a range of scientific pursuits while easily managing 100 percent data growth…

SANTA CLARA and ALISO VIEJO, Calif., Oct. 27, 2011 – Agilent Technologies Inc. (NYSE: A) and Ambry Genetics today announced an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services. “Ambry is intensely focused on delivering the highest quality results for exome sequencing for all of our clients…

LEXINGTON, Mass. and ALISO VIEJO, Calif., October 24, 2011 – RainDance Technologies, Inc., the Digital Biology™ Company, and Ambry Genetics, today announced the launch of a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The ADMESeq™ Research Screening Panel enables researchers to simultaneously interrogate 242 known pharmacogenetic…